CANCER RISK

Published Estimates of Cancer Risk for p16 Mutation Carriers

Site	Population Risk¹	Hereditary Risk
Melanoma	Risk of primary melanoma: <1% by age 50 ~1% by age 80	Risk of primary melanoma: 50% by age 50² 76% by age 80² Risk of second melanomas: Increased risk for second melanomas in p16 mutation carriers previously diagnosed with one melanoma^3,4 15% of patients with multiple primary melanomas (MPM) have a mutation in the p16 gene⁴
Pancreatic	<1% by age 75	Up to 17% by age 75 in some families⁵

Software Citation: DevCan: Probability of Developing or Dying of Cancer Software, Version 6.0. Statistical Research and Applications Branch, National Cancer Institute, 2005. http://srab.cancer.gov/devcan
Bishop DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst. 2002;94:894-903.
Hashemi J, Platz A, Ueno T, Stierner U, Ringborg U, Hannson J. CDKN2A germline mutations in individuals with multiple cutaneous melanomas. Cancer Res. 2000;60:6864-6867.
Monzon J, Liu L, Brill H, et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med. 1998;338:879-887.
Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET, Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer. 2000;87:809-811.